Conversely, circBGN is highly expressed in trastuzumab-resistant HER-2 positive breast cancer cell lines and inhibits ferroptosis of breast cancer cells by regulating the expression of ovarian tumor protease domain-containing deubiquitinase 1 (OTUB) and solute carrier family 7 member 11 [SLC7A11], which reduces the tumor cells’ sensitivity to trastuzumab [146]. Here, ERBB2 is linked to breast carcinoma.